Gland Pharma Limited

Gland Pharma Announces Schedule of Analyst/Institutional Investor Meetings

Gland Pharma announced schedule of Analyst/Institutional Investor Meetings to be held between November 18, 2025 and November 27, 2025.

Gland Pharma Q2FY26 Earnings Call Transcript

Gland Pharma released the transcript of its Q2FY26 earnings call held on November 03, 2025. The call transcript is now available on the company's website.

Gland Pharma Announces Unaudited Financial Results for Q2FY26

Gland Pharma announced its unaudited financial results for Q2FY26, which were approved on November 3, 2025. The results have been published in English and Telugu newspapers and are available on the company website.

Gland Pharma uploads Q2 FY26 Earnings Call recording for investor access

Gland Pharma has uploaded the audio recording of its earnings call for the quarter and half year ended September 30, 2025, held on November 03, 2025, available on its website.

Gland Pharma Reports Strong Q2 FY26 Results, Driven by US Launches and Capacity Expansion

Gland Pharma reported strong Q2 FY26 consolidated revenue growth of 6% YoY and PAT growth of 12% YoY. Key drivers include new US product launches, increased R&D, and expanded GLP-1 capacity, with Cenexi upgrades progressing despite a temporary shutdown impact.

Gland Pharma Reports Strong Q2 FY26 Results with 6% Revenue and 12% PAT Growth YoY

Gland Pharma reported strong Q2 FY26 consolidated results with 6% revenue and 12% PAT growth. Management expects stronger H2 momentum driven by new launches, Cenexi's recovery, and strategic investments.

Gland Pharma Approves Unaudited Financial Results for Quarter Ended September 30, 2025

Gland Pharma board approves unaudited financial results for quarter ended September 30, 2025. Grants employee stock options and recognizes expenses. Results available on the company website.

Gland Pharma announces schedule of Analyst/Institutional Investor Meetings

Gland Pharma announced schedule of Analyst/Institutional Investor Meetings to be held in November 2025 with HBM Partners, Perpetuity Ventures, ICICI Securities and JM Financial.

Gland Pharma to Host Earnings Conference Call for Q2 FY26 on November 3, 2025

Gland Pharma will host an earnings conference call on November 3, 2025, to discuss financial performance and business updates for the quarter and half year ended September 30, 2025.

Certificate under SEBI (Depositories and Participants) Regulations, 2018

Gland Pharma submits compliance certificate under SEBI regulations for dematerialization of securities during the quarter ended 30 September 2025, received from MUFG Intime India Private Limited.

Gland Pharma's 47th AGM Approves All Resolutions, Including FY25 Financials and Dividend

Gland Pharma's 47th AGM Highlights Growth Strategy and FY25 Performance

Gland Pharma Receives USFDA Approval for Vasopressin Injection

Gland Pharma Reports Strong Q1 FY26 with 7% Revenue Growth; Cenexi Achieves Breakeven EBITDA

Gland Pharma uploads Q1 FY26 Earnings Call recording

Gland Pharma Q1FY26 Revenue ₹15,056 Mn, PAT up by 50% YoY

Gland Pharma announces 47th AGM, e-voting details, and dividend information

Gland Pharma clarifies non-receipt of US drug pricing letters amid market slump

Gland Pharma Submits Business Responsibility and Sustainability Report for FY25

Gland Pharma to hold 47th AGM on August 28, 2025; Board recommends ₹18 dividend for FY25

Gland Pharma to host Earnings Conference Call for Q1 FY26 on August 5, 2025